Seattle Genetics reported $-174628000 in Net Income for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Abbvie ABBV:US $ 4490M 446M
Acadia Pharmaceuticals ACAD:US $ -113.06M 69.96M
Agios Pharmaceuticals AGIO:US $ -94.77M 0.15M
Amgen AMGN:US $ 1476M 423M
Astellas Pharma 4503:JP Y -8408M 69294M
Bayer BAYN:GR € 1161M 1076M
Biomarin Pharmaceutical BMRN:US $ 120.8M 178.7M
Clovis Oncology CLVS:US $ -60.17M 4.22M
Daiichi Sankyo 4568:JP Y -27345M 59198M
Eisai 4523:JP Y -12403M 26575M
Esperion Therapeutics ESPR:US $ -56731000 8.39M
Exelixis EXEL:US $ 68.57M 26.59M
Genmab GEN:DC DK 465M 251M
Glaxosmithkline GSK:US $ 1802M 1053M
Immunogen IMGN:US $ -24.14M 13.03M
Insmed INSM:US $ -94621000 18.36M
Karyopharm Therapeutics KPTI:US $ -41399000 80.12M
Mirati Therapeutics MRTX:US $ -188.39M 11.23M
Nektar Therapeutics NKTR:US $ -145.65M 15.94M
Novartis NOVN:VX SF 16308M 13550M
Takeda 4502:JP Y -11358M 69127M
Teva Pharmaceutical TEVA:IT -158000000 448M
Xencor XNCR:US $ 23.59M 49.47M